Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to discovering and developing a new class of precision medicines. The company's core mission is to treat serious diseases by correcting abnormal gene expression through the selective targeting of the chromatin regulatory system. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics was founded in 2015.

Utilizing its proprietary Gene Traffic Control® platform, Foghorn Therapeutics systematically studies and identifies genetically determined dependencies within the chromatin regulatory system, primarily focusing on oncology. The company's lead product candidate, FHD-909, is a selective SMARCA2 inhibitor currently in Phase 1 clinical trials for SMARCA4-mutant cancers, particularly non-small cell lung cancer (NSCLC). The pipeline also includes selective degraders of CBP, EP300, and ARID1B, targeting various solid tumors and hematologic cancers such as ER+ breast cancer, multiple myeloma, and diffuse large B-cell lymphoma. Foghorn has a collaboration agreement with Eli Lilly and Company for the development of FHD-909 and other oncology programs.

Under the leadership of President and CEO Adrian Gottschalk, Foghorn Therapeutics continues to advance its pipeline. The company recently provided a financial update for 2025 and a strategic outlook for 2026, highlighting the progress of FHD-909's Phase 1 dose-escalation, with the first patient dosed in October 2024. Additionally, selective CBP and EP300 degrader programs are on track for IND-enabling studies in 2026. In January 2026, Foghorn completed a $50 million registered direct financing, which is expected to extend its cash runway into the first half of 2028. Ryan Maynard was appointed Chief Financial Officer in February 2026.